ANDA 78157, held by Glenmark Pharmaceuticals. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 78157 (Terbinafine Hydrochloride), held by Glenmark Pharmaceuticals, was first approved by FDA on Jul 2, 2007, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE · tablet;oral | Terbinafine Hydrochloride | Rx |
| Oct 16, 2014 | Supplement 4Manufacturing | Approved | None posted |
| Aug 13, 2008 | Supplement 2Labeling | Approved | None posted |
| Jul 2, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters